Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -13.50p -1.05% 1,266.50p 1,265.50p 1,266.00p 1,287.50p 1,258.00p 1,281.50p 3,539,964 16:35:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,527.9 650.8 65.0 19.0 11,095.42

Smith & Nephew Share Discussion Threads

Showing 801 to 825 of 825 messages
Chat Pages: 33  32  31  30  29  28  27  26  25  24  23  22  Older
DateSubjectAuthorDiscuss
26/7/2018
07:42
Accounts our for 1/2 year - Very much steady as she goes - https://www.investegate.co.uk/smith---38--nephew-plc--sn--/rns/half-year-report/201807260700188013V/ Nothing to shout about (imo) share price reaction will very much depend on forecasts (anyone got them?)
pugugly
04/5/2018
08:24
Elliott called for the company to be broken up last year, after which Mr Bohuon unveiled a cost-cutting plan which he said would deliver $160m of savings by 2022.Analysts at Bernstein said: "S&N's overall performance on both growth and margins has remained disappointing. From here it is all about execution." Daily Telegraph
steeplejack
03/5/2018
10:49
Yes , got to be only a matter of time.
its the oxman
03/5/2018
09:28
Something has to happen here. These guys are vulnerable now. Would not be surprised if Elliot Management makes a return.
basil brush1
03/5/2018
08:25
These less than brilliant results would make it an opportune time to strike for a possible bidder.
broadwood
03/5/2018
08:17
The guidance has been trimmed from revenue growth of 3-4% at the time of the finals to 2-3% now.The suggestion is that things will stabilise and return to a more normal pattern in the rest of the year.Emerging markets are encouraging.Whether this update is worth over 7% off the share price is questionable especially given the corporate activity just now in the sector.Yet the shares have been very strong of late and are vulnerable to top slicing.Maybe I'm too simplistic but I never really worry about my holding in Smith & Nephew.I always feel that if things take an enduring turn for the worse,someone will take the company over.
steeplejack
03/5/2018
07:43
I think you are too pessimistic. I am seeing a P/E of 20 on 2018 EPS before this update, while Stryker is 26. Emerging markets growing at 9% and SN has very little debt.
basil brush1
03/5/2018
07:25
Flat earnings and a P/E of 22 hardly makes it remotely attractive. Also I see plenty of alternative wound care therapies coming through in coming years. Look at Origin WW as an example. Technology been given fast track approval by FDA.
rock star
23/4/2018
19:35
I bought these on the bid speculation awhile back. This sounds interesting. Smith & Nephew was top of the blue chip pile as Dutch giant Philips' first-quarter results revealed strong growth in medical equipment, which was music to the ears of the London-listed maker of artificial shoulders, knees and possibly toes. A further tonic for S&N shares was bid speculation bubbling up again as City traders pointed to US-based Stryker, based in the marvellously named Kalamazoo, Michigan, being a possible suitor after four years ago confirming it had been been looking at a potential takeover.
broadwood
23/4/2018
15:48
Why today? News?
its the oxman
23/4/2018
15:43
Is this the big breakout?
basil brush1
04/4/2018
16:13
Any views on new CEO? He sold Alere to Abbott in 2017 for $5.3 billion. No one seems to care?
basil brush1
24/1/2018
08:00
Scope to have a run back over 1300p with lower tax guidance.
its the oxman
22/1/2018
10:20
Strykers full results are on Jan 30, the next few weeks will be interesting. Stryker provides 2017 preliminary net sales results By GlobeNewswire, January 09, 2018, 08:15:00 AM EDT Kalamazoo, Michigan - January 9, 2018 - Stryker Corporation (NYSE:SYK) announced today that preliminary results for the fourth quarter and full year 2017 were: Preliminary Fourth Quarter Highlights Net sales grew 10.0% to $3.5 billion (8.7% constant currency) Orthopaedics 8.1 % or 6.8 % constant currency MedSurg 10.9 % or 9.8 % constant currency Neurotechnology and Spine 11.5 % or 10.3 % constant currency Preliminary Full Year Highlights Net sales grew 9.9% to $12.4 billion (9.8% constant currency) Orthopaedics 6.6 % or 6.5 % constant currency MedSurg 13.6 % or 13.4 % constant currency Neurotechnology and Spine 8.2 % or 8.3 % constant currency Preliminary consolidated net sales of $3.5 billion and $12.4 billion increased 10.0% and 9.9% as reported in the fourth quarter and full year. Excluding the impact of foreign currency and acquisitions, net sales increased 8.1% and 7.1% in the fourth quarter and full year. Based on our year-to-date performance, we expect 2017 adjusted net earnings per diluted share(a) to be toward the high end of our previously announced range of $6.45 to $6.50. The foreign currency exchange impact on net sales in the fourth quarter was positive of approximately 1.2% and nominal in the full year. "We continued our momentum with strong organic sales growth of 8% for the fourth quarter and 7% for the full year," said Kevin A. Lobo, Chairman and Chief Executive Officer. "I would like to thank our teams for delivering these results, which were well balanced across businesses and geographies. We are also driving innovation through R&D and acquisitions that will fuel future growth. These investments will enable us to deliver sales growth at the high end of med tech and leveraged earning gains."
basil brush1
22/1/2018
10:16
Good luck! IMO these UK companies that report in foreign currencies lose out both ways, because the US investors dont understand the accounting while the UK investors are confused by the currency. SN has fallen nearly £2 since October, the market seems to be discounting the worst. But meanwhile Stryker keeps marching on.
basil brush1
21/1/2018
12:42
Bloody well hope there is a bid. Sold a load just under 1400p and now bought them back and more besides. Poor performer over 12 months. Hoping for a bounce regardless with results. We will see.
its the oxman
19/1/2018
08:39
imo lots of support at 1230. the big question is will there be a bid before the new CEO is appointed? looks vulnerable as share price has not changed in dollar terms in nearly 4 years. Stryker has doubled in the same period.
basil brush1
18/1/2018
16:25
Could have further to fall (imo) 11-Oct-17Citigroup Sell Now 1,233.50 Then 1,359.00 New target 1,160.00
pugugly
17/1/2018
11:18
these were 1440 less than 3 months back. are the powers than be managing the price down so to get a bid in at not much higher than the October highs?
basil brush1
16/1/2018
20:07
As a quality operator surely SN will get some bid speculation this year. Must be so tempting now it's slipped back to 1250p.
its the oxman
05/1/2018
12:29
nice to finally see a rally. S&N has underperformed stryker by 75% over two years in dollar terms. S&N ADRs are unchanged while stryker has gone up by 75%. unbelievable.
basil brush1
02/1/2018
21:54
this is a real dog stock. having tracked stryker closely for decades, this has incredibly under-performed by a massive 75% in the last two years. three years ago stryker was only slightly bigger than S&N, now it is four times the size.
basil brush1
15/12/2017
14:05
Anyone know why these are trading at such a big discount to Stryker? Is it because SN does not have enough debt on board? I have SN on a PE ratio of 18 from Google Finance, with SYK at 35.
basil brush1
13/12/2017
14:58
these shares seem to have dodgy knees.... anyone know what happened with Elliot Advisors? http://www.telegraph.co.uk/business/2017/11/03/smith-nephew-boss-defends-strategy-elliott-circles/
basil brush1
13/11/2017
12:15
Dodgy knees and hips aren't going away - keep buying.
its the oxman
Chat Pages: 33  32  31  30  29  28  27  26  25  24  23  22  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20181017 19:00:36